ClinicalTrials.gg
Not yet recruitingNCT07501273No acronymUpdated Nov 18, 2026

Analgesic Effect of a Biophotonic Foot Massage Cream

An interventional study of Biophotonic cosmetic massage cream and Placebo in Musculoskeletal Pain, sponsored by University of Seville. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Seville · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the effectiveness of a biophotonic cosmetic massage cream in reducing musculoskeletal foot pain in adults. Participants with pain in one or both feet attending the Podiatry Clinical Area of the University of Seville will be randomly assigned to receive either the investigational cream or a placebo cream with similar characteristics. The assigned product will be applied topically to the painful area twice daily for 10 consecutive days. Pain intensity, pressure pain threshold, foot function, and health-related quality of life will be assessed during the study.

Read the detailed description

Foot pain is a common and clinically relevant problem in adults, and musculoskeletal foot pain is frequently managed with oral and topical pharmacological treatments. However, conventional analgesic and anti-inflammatory therapies may be associated with adverse effects, which supports the investigation of potentially safer conservative alternatives. This study is designed as a randomized, placebo-controlled, parallel-group clinical trial to assess whether a biophotonic cosmetic massage cream can significantly reduce musculoskeletal foot pain in adults.

Eligible participants will be adults with musculoskeletal pain in one or both feet who attend the Podiatry Clinical Area of the University of Seville. Participants will be recruited consecutively in the context of routine clinical care and will be randomly assigned in a 1:1 ratio to either an experimental group receiving the biophotonic cosmetic massage cream or a control group receiving a placebo with similar characteristics.

The intervention consists of topical self-application of the assigned product to the painful area of the foot twice daily for 10 consecutive days, following instructions provided by the research team. The primary outcome will be pain intensity measured using the Numeric Pain Rating Scale (NPRS-11). Secondary outcomes will include pressure pain threshold measured with a Wagner FPK 10 pressure algometer, foot pain and function assessed with the Foot Function Index, and health-related quality of life assessed with the SF-12 questionnaire.

The planned sample size is 170 participants, corresponding to 85 per group, allowing for an anticipated 20% loss to follow-up. Statistical analyses will compare changes between groups and over time, with a significance level of 0.05 and analysis preferably following the intention-to-treat principle.

02

Conditions studied

  • Musculoskeletal Pain

Browse trials for

Keywords

  • Foot pain
  • Musculoskeletal pain
  • Biophotonic cream
  • Topical treatment
  • Placebo
  • Randomized clinical trial
  • Podiatry
03

In context

Musculoskeletal Pain

518 studies on the registry are indexed under Musculoskeletal Pain; 127 are open to participants now.

This study's planned enrollment of 170 is above the median of 69 across 373 interventional studies indexed under Musculoskeletal Pain.

Browse Musculoskeletal Pain studies →

Lead sponsor

University of Seville is the lead sponsor of 131 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • Patients attending the Podiatry Clinical Area of the University of Seville.
  • Presence of musculoskeletal pain in one or both feet at the initial assessment.
  • Ability to understand the study information and provide written .
  • Ability to follow study instructions and complete study assessments.
  • Intact skin at the application site.

Exclusion criteria

Exclusion Criteria:

  • Foot pain of non-musculoskeletal origin, or pain mainly attributable to infectious, vascular, tumoral, severe neurological, or decompensated systemic diseases.
  • Wounds, ulcers, burns, dermatitis, skin infections, or any active skin disorder at the application site.
  • Known allergy, , or previous adverse reaction to any component of the cream or placebo.
  • Concomitant use of analgesic, anti-inflammatory, or topical treatments on the foot that may interfere with efficacy assessment, unless a is established.
  • Recent infiltrations, surgery, or invasive treatment on the foot or ankle that may alter pain evolution during the study.
  • Pregnancy or breastfeeding.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Biophotonic cosmetic massage cream

    Biophotonic cosmetic massage cream

    Other: Biophotonic cosmetic massage cream

  • Placebo comparator
    Placebo

    Topical self-application of the placebo cream to the painful area of the foot, twice daily for 10 consecutive days, according to the instructions provided by the research team.

    Other: Placebo

Interventions

  • OtherBiophotonic cosmetic massage cream

    Topical self-application of the investigational cosmetic massage cream to the painful area of the foot, twice daily for 10 consecutive days, according to the instructions provided by the research team.

  • OtherPlacebo

    Topical self-application of the placebo cream to the painful area of the foot, twice daily for 10 consecutive days, according to the instructions provided by the research team.

06

What researchers measure

Primary outcomes

  1. Change in pain intensity measured with the Numeric Pain Rating Scale (NPRS-11)

    Pain intensity will be assessed using the Numeric Pain Rating Scale (NPRS-11), which minimum value is 0 (that means no pain, the best result) and maximum value is 10 (that means the worst pain the participant could withstand). The primary endpoint will be the change in pain score from baseline to the end of the 10-day intervention period.

    Time frame: Baseline to Day 10

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Sep 2027, 6 months later.

Of 225 non-industry interventional studies with no phase under Musculoskeletal Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's planned 6 months is below that.

Counting every sponsor, half of 238 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Mar 2027, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Mar 30, 2026
StartEst.
Mar 1, 2027was Sep 2026
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Mar 1, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Start date Sep 1, 2026→Mar 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07501273
Responsible party
Pedro V. Munuera-Martínez (Ph.D, University of Seville) — Principal investigator
First posted
Mar 30, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Pedro Vicente Munuera-Martínez, Ph.D
Contact
pmunuera@us.es
+34696437996

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion